Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) EBIT (2018 - 2025)

Black Diamond Therapeutics' EBIT history spans 6 years, with the latest figure at -$17.6 million for Q4 2025.

  • For Q4 2025, EBIT rose 3.64% year-over-year to -$17.6 million; the TTM value through Dec 2025 reached $12.5 million, up 115.89%, while the annual FY2025 figure was $12.5 million, 115.89% up from the prior year.
  • EBIT reached -$17.6 million in Q4 2025 per BDTX's latest filing, down from -$11.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $54.5 million in Q1 2025 to a low of -$35.4 million in Q3 2021.
  • Average EBIT over 3 years is -$15.2 million, with a median of -$18.3 million recorded in 2024.
  • Peak YoY movement for EBIT: crashed 138.47% in 2021, then skyrocketed 369.34% in 2025.
  • A 3-year view of EBIT shows it stood at -$35.4 million in 2021, then soared by 48.32% to -$18.3 million in 2024, then increased by 3.64% to -$17.6 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's EBIT are -$17.6 million (Q4 2025), -$11.0 million (Q3 2025), and -$13.4 million (Q2 2025).